Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 6, 2025American Journal of Nephrology

Intensive vs. Less Intensive Blood Pressure Control in Chronic Kidney Disease: A Systematic Review and Meta-analysis of Clinical Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

PFParisa FallahtaftiDSDavood Semirani-NezhadSMSaba Maleki

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis reveals intensive blood pressure control does not improve outcomes in chronic kidney disease patients, indicating a need for further studies.

Key Points

  • Intensive blood pressure control does not significantly reduce all-cause mortality in chronic kidney disease patients.
  • The analysis included 11 randomized controlled trials with a total of 8,740 participants for comparison.
  • Meta-analysis showed no meaningful differences in renal outcomes between intensive and standard blood pressure control.
  • Findings suggest that new long-term studies are necessary to determine optimal blood pressure targets for CKD patients.

Cite This Study

Fallahtafti et al. (2025) studied this question.

synapsesocial.com/papers/689a0fa0e6551bb0af8d1884https://doi.org/10.1159/000547812
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluating the Renal Implications of Intensive Versus Standard Blood Pressure Control in Chronic Kidney Disease: A Systematic Review of Randomized Trials2025
  2. 2Pros and cons of lower blood pressure targets in chronic kidney disease2025
  3. 3BLOOD PRESSURE LEVELS AND THE PROGRESSION OF CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW2025
  4. 4Effects of Intensive Systolic Blood Pressure Control on Kidney Outcomes in Patients With and Without <scp>CKD</scp>: A Post Hoc Analysis of <scp>SPRINT</scp> and <scp>ACCORD</scp>‐<scp>BP</scp> Trials2025
  5. 5Effects of intensive blood pressure control on cardio-kidney outcomes by KDIGO risk categories: a Post Hoc analysis of ACCORD-BP and SPRINT trials2026